Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
A phase 3 trial of Pembrolizumab, Carboplatin, Docetaxel and Cisplatin in endometrial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) is a phase 3 interventional study registered as NCT05173987 by Merck Sharp & Dohme LLC, with 280 participants enrolled, started 2022-02-03 and due to reach its primary completion in 2027-05-27. Interventions recorded: pembrolizumab, carboplatin, paclitaxel, docetaxel and cisplatin.
Similar pages
not linked directly; found by shared links- TrialStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Shares Docetaxel, Cisplatin, Endometrial cancer, Merck & Co. (MSD) and the tag pipeline.
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialGYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
Shares Endometrial cancer, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Docetaxel, Cisplatin, Carboplatin and the tag pipeline.